866-997-4948 (US-Canada Toll Free)

Immunovaccine, Inc. Product Pipeline Review 2012

Published By :

Global Markets Direct

Published Date : 2012-10-31

Category :

Pharmaceutical

No. of Pages : 84

Product Synopsis


Immunovaccine, Inc. Product Pipeline Review 2012

Global Market Directs pharmaceuticals report, ImmunoVaccine Technologies Inc. Product Pipeline Review 2012 provides data on the ImmunoVaccine Technologies Inc.s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. 

This report is built using data and information sourced from Global Markets Directs proprietary databases, ImmunoVaccine Technologies Inc.s corporate website, SEC filings, investor presentations and featured press releases, both from ImmunoVaccine Technologies Inc. and industry-specific third party sources, put together by Global Markets Directs team. 

Scope

  • ImmunoVaccine Technologies Inc. Brief ImmunoVaccine Technologies Inc. overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of ImmunoVaccine Technologies Inc. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of ImmunoVaccine Technologies Inc. with complete description of the products developmental history, mechanism of action, therapeutic class, target and major milestones. 
  • Recent updates of the ImmunoVaccine Technologies Inc.s pipeline in the last quarter. 
  • Key discontinued and dormant projects. 
  • Latest news and deals relating to the products.

Reasons to buy

  • Evaluate ImmunoVaccine Technologies Inc.s strategic position with total access to detailed information on its product pipeline. 
  • Assess the growth potential of ImmunoVaccine Technologies Inc. in its therapy areas of focus. 
  • Identify new drug targets and therapeutic classes in the ImmunoVaccine Technologies Inc.s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. 
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. 
  • Exploit collaboration and partnership opportunities with ImmunoVaccine Technologies Inc.. 
  • Avoid Intellectual Property Rights related issues. 
  • Explore the dormant and discontinued projects of ImmunoVaccine Technologies Inc. and identify potential opportunities in those areas.

Table Of Content

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Immunovaccine, Inc. Snapshot 7
Immunovaccine, Inc. Overview 7
Key Information 7
Key Facts 7
Immunovaccine, Inc. – Research and Development Overview 8
Key Therapeutic Areas 8
Immunovaccine, Inc. – Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products –  Monotherapy 12
Pipeline Products – Combination Treatment Modalities 13
Immunovaccine, Inc. – Pipeline Products Glance 14
Immunovaccine, Inc. Clinical Stage Pipeline Products 14
Phase I Products/Combination Treatment Modalities 14
Immunovaccine, Inc. – Early Stage Pipeline Products 15
Pre-Clinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
Immunovaccine, Inc. – Drug Profiles 17
Anthrax Vaccine 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Cocaine Addiction Vaccine 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
DPX-0907 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
DPX-Survivac 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
DPX-Survivac + Low Dose Cyclophosphamide 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Hepatitis B Vaccine 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
HPV Vaccine 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
IRX-2 + DepoVax 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Malaria Vaccine 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Pandemic Influenza Vaccine 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Respiratory Syncytial Virus Vaccine 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Vaccine For Multifiloviruses 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Immunovaccine, Inc. – Pipeline Analysis 32
Immunovaccine, Inc. – Pipeline Products by Therapeutic Class 32
Immunovaccine, Inc. – Pipeline Products by Route of Administration 33
Immunovaccine, Inc. – Pipeline Products By Mechanism of Action 34
Immunovaccine, Inc. –  Recent Pipeline Updates 35
Immunovaccine, Inc. - Discontinued Pipeline Products 38
Discontinued Pipeline Product Profiles 38
DPX-Pseudomonas 38
Immunovaccine, Inc. – Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Immunovaccine, Inc., Recent Developments 40
Immunovaccine, Inc.- Press Release 40
Oct 09, 2012: Immunovaccine Reports Positive Interim Results From Phase I Study Of Ovarian Cancer Vaccine Candidate DPX-Survivac 40
Aug 06, 2012: Immunovaccine Announces Publication Of Positive Clinical Trial Results For DPX-0907 In Journal Of Translational Medicine 41
Jun 20, 2012: Immunovaccine Announces Presentation Of DPX-Survivac Data At Federation of Clinical Immunology Societies Conference 43
Jun 04, 2012: Immunovaccine Presents Positive Phase I Results Of DPX-0907 In Multiple Cancers At ASCO Annual Meeting 2012 44
May 29, 2012: Immunovaccine To Present Clinical Data On DPX-0907 Cancer Vaccine At 2012 ASCO Annual Meeting 45
Apr 03, 2012: Immunovaccine Presents Findings Of Cancer Vaccine Studies At AACR Meeting 45
Jan 04, 2012: Immunovaccine Initiates Phase I Trial Of DPX-Survivac Cancer Vaccine 46
Dec 10, 2009: Immunovaccine Inc. Announces Approval Of Investigational Drug Application For Its Therapeutic Cancer Vaccine, DPX-0907 47
Dec 09, 2009: Immunovaccine Receives Clearance From FDA For Phase 1 Clinical Trial For Its Therapeutic Cancer Vaccine, DPX-0907 47
Jul 14, 2009: ImmunoVaccine Technologies Licenses Immunotope’s Breast, Ovarian and Prostate Cancer Antigens 48
Financial Deals Landscape 49
Immunovaccine, Inc., Deals Summary 49
Immunovaccine, Inc., Pharmaceuticals & Healthcare, Deal Details 51
Partnerships 51
Immunovaccine Enters Into Co-Development Agreement With Weill Cornell Medical College For Anti-Cocaine Vaccine 51
ImmunoVaccine Technologies Enters Into Research Agreement With CIMAB 52
Immunovaccine Technologies Enters Into Research Agreement With OncoTherapy Science 53
ImmunoVaccine Enters Into Agreement With IRX Therapeutics 54
Immunovaccine Enters Into Co-Development Agreement With Oncothyreon 55
Immunovaccine Enters Into Research Agreement With Vaxil BioTherapeutics 56
ImmunoVaccine Enters Into Research Agreement With Dana-Farber 57
ImmunoVaccine Enters Into Research Agreement With National Cancer Institute 62
Immunovaccine Expands Research Agreement With Defence Research And Development Canada 63
ImmunoVaccine Technologies Enters Into Agreement With Scancell 64
ImmunoVaccine Enters Into Research Agreement With Yokohama City University 65
ImmunoVaccine Technologies Enters Into Research Agreement With FIT Biotech 66
ImmunoVaccine Technologies Enters Into Agreement With NRC Institute for Biodiagnostics 67
ImmunoVaccine Technologies Enters Into An Agreement With Defence Research and Development Canada 68
ImmunoVaccine Enters Into Collaboration Agreement With National Institutes of Health 69
Bioject Medical Technologies Enters Into Research Collaboration With ImmunoVaccine Technologies 70
ImmunoVaccine Technologies Enters Into Co-Development Agreement With DRDC 71
Licensing Agreements 72
Immunovaccine Enters Into License Agreement With Merck 72
Immunotope Enters Into Licensing Agreement With ImmunoVaccine Technologies 74
Pharmexa Enters Into Licensing Agreement With ImmunoVaccine Technologies 75
Equity Offering 76
Immunovaccine Completes Private Placement Of Common Stock For $2.8 Million 76
Immunovaccine Completes Public Offering Of $7.22 Million 78
Acquisition 80
ImmunoVaccine Completes Reverse Acquisition Of Rhino Resources 80
ImmunoVaccine Acquires Immunotope 81

Appendix 83
Methodology 83
Coverage 83
Secondary Research 83
Primary Research 83
Expert Panel Validation 83
Contact Us 84
Disclaimer 84

List of Tables


Immunovaccine, Inc., Key Information 7
Immunovaccine, Inc., Key Facts 7
Immunovaccine, Inc. Pipeline by Indication, 2012 9
Immunovaccine, Inc. Pipeline by Stage of Development, 2012 11
Immunovaccine, Inc. Monotherapy Products in Pipeline, 2012 12
Immunovaccine, Inc. Combination Treatment Modalities in Pipeline, 2012 13
Immunovaccine, Inc. Phase I, 2012 14
Immunovaccine, Inc. Pre-Clinical, 2012 15
Immunovaccine, Inc. Discovery, 2012 16
Immunovaccine, Inc. Pipeline By Therapeutic Class, 2012 32
Immunovaccine, Inc. Pipeline By Route of Administration, 2012 33
Immunovaccine, Inc. Pipeline Products By Mechanism of Action, 2012 34
Immunovaccine, Inc. Recent Pipeline Updates, 2012 35
Immunovaccine, Inc. - Discontinued Pipeline Products, 2012 38
Immunovaccine, Inc., Subsidiaries 39
Immunovaccine, Inc., Deals Summary 49
Immunovaccine Enters Into Co-Development Agreement With Weill Cornell Medical College For Anti-Cocaine Vaccine 51
ImmunoVaccine Technologies Enters Into Research Agreement With CIMAB 52
Immunovaccine Technologies Enters Into Research Agreement With OncoTherapy Science 53
ImmunoVaccine Enters Into Agreement With IRX Therapeutics 54
Immunovaccine Enters Into Co-Development Agreement With Oncothyreon 55
Immunovaccine Enters Into Research Agreement With Vaxil BioTherapeutics 56
ImmunoVaccine Enters Into Research Agreement With Dana-Farber 57
ImmunoVaccine Enters Into Research Agreement With National Cancer Institute 62
Immunovaccine Expands Research Agreement With Defence Research And Development Canada 63
ImmunoVaccine Technologies Enters Into Agreement With Scancell 64
ImmunoVaccine Enters Into Research Agreement With Yokohama City University 65
ImmunoVaccine Technologies Enters Into Research Agreement With FIT Biotech 66
ImmunoVaccine Technologies Enters Into Agreement With NRC Institute for Biodiagnostics 67
ImmunoVaccine Technologies Enters Into An Agreement With Defence Research and Development Canada 68
ImmunoVaccine Enters Into Collaboration Agreement With National Institutes of Health 69
Bioject Medical Technologies Enters Into Research Collaboration With ImmunoVaccine Technologies 70
ImmunoVaccine Technologies Enters Into Co-Development Agreement With DRDC 71
Immunovaccine Enters Into License Agreement With Merck 72
Immunotope Enters Into Licensing Agreement With ImmunoVaccine Technologies 74
Pharmexa Enters Into Licensing Agreement With ImmunoVaccine Technologies 75
Immunovaccine Completes Private Placement Of Common Stock For $2.8 Million 76
Immunovaccine Completes Public Offering Of $7.22 Million 78
ImmunoVaccine Completes Reverse Acquisition Of Rhino Resources 80
ImmunoVaccine Acquires Immunotope 81

List of Figures


Immunovaccine, Inc. Pipeline by Indication, 2012 9
Immunovaccine, Inc. Pipeline by Stage of Development, 2012 11
Immunovaccine, Inc. Monotherapy Products in Pipeline, 2012 12
Immunovaccine, Inc. Combination Treatment Modalities in Pipeline, 2012 13
Immunovaccine, Inc. Pipeline By Therapeutic Class, 2012 32
Immunovaccine, Inc. Pipeline By Route of Administration, 2012 33
Immunovaccine, Inc. - Pipeline Products By Mechanism of Action, 2012 34

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *

Upcoming Reports

  • Epinephrine Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019

    By - Transparency

    Epinephrine or adrenaline is a hormone secreted by adrenal glands in the blood stream. It is one of the two common hormones (the other being glucagon) that is responsible for glycogen breakdown. Secretion of epinephrine is characterized by the presence of extreme emotions such as anxiety or anger thereby resulting in elevated levels of blood pressure along with increased muscle strength and high sugar metabolism. Under strenuous conditions signals are transmitted to brain and brain in turn sends nerve impulses to the adrenal glands in the kidneys and result in the release or secretion of...

  • Poland: boring or sinking machinery market

    By - Williams and Marshal Strategy

    This report presents a comprehensive overview of the boring or sinking machinery market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the boring or sinking machinery market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report...

  • Middle Distillate Refining Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019

    By - Transparency

    Globally refiners continue to face several challenges as environmental policies are becoming increasingly stringent. The profitability of refiner’s is influenced because of strict regulations on sulphur content of gasoline & diesel oil and curbs on refinery emissions. Agencies such as the International Maritime Organizationhas already proposed changes in specifications of bunker fuel oil. These regulations will drastically impact the refinery’s profitability which would then have a tough time increasing or maintaining current refining margins. Thus those refineries which...